- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00858403
Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation
Phase II Study of Dasatinib in Advanced Non-small Cell Lung Cancer With Ex Vivo and In Vivo Assessment of Tumor Target Modulation
Studieoversikt
Detaljert beskrivelse
Cycle 1 Day 1 (C1D1): Patients will have complete history and physical (H&P), complete blood count (CBC), complete metabolic panel (CMP) and electrocardiogram (EKG) on day 1. Each cycle is 28 days. The C1D1 EKG can be omitted if the patient has no new cardiac symptoms and has not starting taking any medication known to affect QT corrected for heart rate (QTc) prolongation. Any residual toxicity from prior therapy for cancer will be recorded. Blood will be drawn for assessment of serum markers. The patient will begin dasatinib at the starting C1D1 on a daily basis.
Cycle 1 Day 10-20 (C1D10-20): Patients will have a second biopsy to obtain additional tumor material to examine biological effects of dasatinib on signaling pathways. Dasatinib will be taken first thing in the morning and the patient will log the time. Blood will also be drawn for pharmacokinetic assessments of dasatinib levels in plasma and the time recorded. Four FNA aspirates and 2 core biopsies can be obtained either at the bedside for palpable lesions or through appropriate image-guided techniques (CT or US) at the discretion of the treating physician in consultation with radiology. The time of the biopsy will be recorded. One core biopsy should be immediately fixed in formalin and the other core biopsy should be snap frozen in liquid nitrogen.
Cycle 2 Day 1 (C2D1): Patients will be seen by the treating physician and have complete H&P, CBC, and CMP. Blood will be drawn for assessment of serum markers. Toxicity of dasatinib will be assessed. The patient will continue to take daily doses of dasatinib on a daily basis.
Cycle 2 Day 22 (C2D22): Patients will undergo reevaluation for tumor measurements. This assessment can occur on C2D22 ±7 days.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Florida
-
Tampa, Florida, Forente stater, 33612
- H. Lee Moffitt Cancer Center & Research Institute
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histologically or cytologically documented diagnosis of NSCLC that is advanced/metastatic (Stage IIIB/IV).
- Performance Status (ECOG) 0-2
- Previous chemotherapy with the exception of dasatinib. Patients who have had any type of previous chemotherapy regimens for non-small cell lung cancer are eligible.
Adequate Organ Function:
- Total bilirubin < 2.0 times the institutional Upper Limit of Normal (ULN)
- Hepatic enzymes (AST, ALT ) ≤ 2.5 times the institutional ULN
- Serum Na, K+, Mg2+, Phosphate and Ca2+≥ Lower Limit of Normal (LLN)
- Serum Creatinine < 1.5 time the institutional ULN
- Hemoglobin, Neutrophil count, Platelets, prothrombin time (PT), partial thromboplastin time (PTT) all Grade 0-1
- Ability to take oral medication
Concomitant Medications:
- Agree to discontinue St. Johns Wort while receiving dasatinib therapy
- Agree that IV bisphosphonates will be withheld for the first 8 weeks of dasatinib therapy due to risk of hypocalcemia.
Women of childbearing potential (WOCBP):
- A negative serum or urine pregnancy test within 72 hours prior to the start of study drug administration
- Persons of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped Prior to study enrollment.
- Signed written informed consent including a HIPAA form according to institutional Guidelines
Exclusion Criteria:
- No malignancy [other than the one treated in this study] which required radiotherapy or systemic treatment within the past 5 years.
- Prior dasatinib therapy.
Concurrent medical condition which may increase the risk of toxicity, including:
- Patients with severe pulmonary disease that increases the risk of toxicity related to dasatinib-induced pleural effusions. This includes chronic obstructive pulmonary disease or pleural effusions (malignant or benign) requiring chronic oxygen therapy or patients that have had prior pneumonectomy. Patients that have a pulmonary embolism and require oxygen therapy will be excluded but not those patients who have a pulmonary embolism but do not require oxygen therapy. Patients with active pleural effusions not controlled with pleurodesis will be excluded.
Cardiac Symptoms; any of the following should be considered for exclusion:
- Uncontrolled angina, congestive heart failure or MI within (6 months)
- Diagnosed congenital long QT syndrome
- Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
- Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)
- Patients with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration
History of significant bleeding disorder unrelated to cancer, including:
- Diagnosed congenital bleeding disorders
- Diagnosed acquired bleeding disorder within one year
- Ongoing or recent (≤ 3 months) significant gastrointestinal bleeding
Concomitant Medications, any of the following should be considered for exclusion:
Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes including: (Patients must discontinue drug 7 days prior to starting dasatinib)
- quinidine, procainamide, disopyramide
- amiodarone, sotalol, ibutilide, dofetilide
- erythromycin, clarithromycin
- chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide
- cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine.
Women:
- unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after cessation of study drug,or
- have a positive pregnancy test at baseline
- pregnant or breastfeeding
- Prisoners or persons who are compulsorily detained (involuntarily incarcerated)for treatment of either a psychiatric or physical (e.g., infectious) illness
- Patients on systemic anticoagulation at risk of bleeding related to tumor biopsy that cannot be off anticoagulation per the discretion of their physician.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Treatment with Dasatinib
Dasatinib 140 mg orally (po) every day starting Day #1, continuous dosing.
This dose was chosen based on the current experience in patients with solids tumors who have had prior chemotherapy.
|
Take tablets of Dasatinib by mouth once a day.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of Participant Progressors vs. Non-progressors With Tumor Response
Tidsramme: 1 year, 4 months
|
We planned to assess whether the extent of inhibition of extracellular signal-regulated protein kinase (ERK) phosphorylation in lung cancer cells exposed ex vivo to dasatinib significantly differed between patients categorized as progressors or non-progressors through standard Response Evaluation Criteria In Solid Tumors (RECIST)
|
1 year, 4 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of Participants With Response to Dasatinib
Tidsramme: 1 year, 4 months
|
We planned to estimate the single agent response rate to dasatinib in this patient population
|
1 year, 4 months
|
Number of Participants With Progression Free Survival (PFS) at 6 Months
Tidsramme: 1 year, 4 months
|
We planned to estimate the 6 month progression free survival rate of dasatinib in this patient population.
|
1 year, 4 months
|
Number of Participants With Serious Adverse Events (SAEs)
Tidsramme: 1 year, 4 months
|
We evaluated toxicity of dasatinib in this patient population.
|
1 year, 4 months
|
Number of Participant Progressors vs. Non-Progressors With Inhibition Response
Tidsramme: 1 year, 4 months
|
We planned to assess whether the extent of inhibition of proto-oncogene tyrosine-protein kinase (SRC) and protein kinase B (Akt) phosphorylation in lung cancer cells exposed ex vivo and in vivo to dasatinib significantly differs between patients categorized as progressors or non-progressors through standard RECIST criteria.
|
1 year, 4 months
|
Correlation Between Extent of Inhibition and Concentration of Dasatinib
Tidsramme: 1 year, 4 months
|
We planned to explore whether the extent of inhibition of ERK, SRC and Akt phosphorylation in lung cancer cells exposed ex vivo to dasatinib will correlate with the drug concentration of dasatinib.
|
1 year, 4 months
|
Correlation Between Mutation and Inhibition and to Disease Control Rate and Response
Tidsramme: 1 year, 4 months
|
To analyze Kras and epidermal growth factor receptor (EGFR) mutation and their correlation to the ERK pathway inhibition and to disease control rate and response.
|
1 year, 4 months
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Eric Haura, M.D., H. Lee Moffitt Cancer Center and Research Institute
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i luftveiene
- Neoplasmer
- Lungesykdommer
- Neoplasmer etter nettsted
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Lungeneoplasmer
- Karsinom, ikke-småcellet lunge
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antineoplastiske midler
- Proteinkinasehemmere
- Dasatinib
Andre studie-ID-numre
- MCC-15656
- CA180214 (Annen identifikator: Bristol-Myers Squibb)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Lungekreft
-
Yonsei UniversityFullført
-
Novartis PharmaceuticalsFullførtNevroendokrine svulster | Avansert NET av GI Origin | Advanced NET of Lung OriginForente stater, Colombia, Italia, Taiwan, Storbritannia, Belgia, Tsjekkia, Tyskland, Japan, Saudi-Arabia, Canada, Nederland, Spania, Korea, Republikken, Libanon, Østerrike, Kina, Hellas, Sør-Afrika, Thailand, Ungarn, Tyrkia, Polen, Slov... og mer
-
The Cleveland ClinicTilbaketrukketOne Lung Ventillation (OLV) | To lungeventilasjon (TLV) | Positivt End Expiratory Pressure (PEEP) | Null sluttekspirasjonstrykk (ZEEP)
-
Assiut UniversityHar ikke rekruttert ennåLungekreft | Lungeskade | Bleb Lung
-
RenJi HospitalRekrutteringMultiple Synchronous Lung Cancers (MSLC)Kina
-
Poitiers University HospitalFullførtEndobronchial Transbronchial Needle Aspiration Lung Cancer Procore
-
University of LorraineFullførtBare barn | Spontan pneumothorax | Idiopatisk pneumotoraks | Bleb LungFrankrike
-
AHS Cancer Control AlbertaCross Cancer InstituteFullførtOmfattende Stage Small Cel Lung CancerCanada
-
Damascus UniversityUniversity Children's HospitalFullførtEsophageal atresi | One Lung Ventilation OLV | Hydrocystoma | Pneumonektomi | Pleura; AbscessDen syriske arabiske republikk
-
Ministry of Health, Saudi ArabiaHar ikke rekruttert ennåLuftveissykdom | Prematuritet | Ventilator Lung; Nyfødt
Kliniske studier på Dasatinib
-
Bristol-Myers SquibbFullførtFarmakokinetisk studie hos friske deltakereForente stater
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Fullført
-
Hyoung Jin KangHar ikke rekruttert ennåAkutt lymfatisk leukemi, pediatrisk
-
National Cancer Institute (NCI)NRG OncologyAvsluttetTilbakevendende egglederkarsinom | Tilbakevendende ovariekarsinom | Tilbakevendende primært peritonealt karsinom | Klarcellet ovariecystadenokarsinom | Endometrie klarcellet adenokarsinom | Tilbakevendende livmorkreftForente stater
-
Xspray Pharma ABQPS Bioserve India Pvt LimitedFullført
-
National Cancer Institute (NCI)TilbaketrukketHematopoetisk og lymfoid celle-neoplasma | Avansert lymfom | Avansert malignt solid neoplasma | Refraktær lymfom | Ildfast malignt fast neoplasma | Refraktært plasmacellemyelomForente stater
-
Jonsson Comprehensive Cancer CenterBristol-Myers SquibbFullført
-
Peking University Cancer Hospital & InstituteUkjentGastrointestinal stromal svulstKina
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Fullført
-
Kanto CML Study GroupUkjentMyelogen leukemi, kronisk, kronisk faseJapan